The Role of Reactive Nitrogen and Oxygen Intermediates in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 199-211

  Mashmoushi, Ahmad K ^a   Gilkeson, Gary S ^b   Oates, Jim C ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863866599     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10012-9     Document Type: Chapter

References (129)

1. Lafyatis R., Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007, 9. 222-222.
2. Oates J.C., Gilkeson G.S. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol 2006, 121:243-250.
3. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956, 11:298-300.
4. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
5. Vignais P.V. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002, 59:1428-1459.
6. Wei C.-C., Wang Z.-Q., Durra D., Hemann C., Hille R., Garcin E.D., et al. The three nitric-oxide synthases differ in their kinetics of tetrahydrobiopterin radical formation, heme-dioxy reduction, and arginine hydroxylation. J Biol Chem 2005, 280:8929-8935.
7. Turrens J.F., Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980, 191:421-427.
8. Chance B., Sies H., Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979, 59:527-605.
9. Squadrito G.L., Pryor W.A. Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med 1998, 25:392-403.
10. Sies H. Oxidative stress: oxidants and antioxidants. Experimental Physiology 1997, 82:291-295.
11. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95.
12. D'Autreaux B., Toledano M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007, 8:813-824.
13. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001, 11:173-186.
14. Ji L.L., Gomez-Cabrera M.-C., Vina J. Role of free radicals and antioxidant signaling in skeletal muscle health and pathology. Infect Disord Drug Targets 2009, 9:428-444.
15. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160:1-40.
16. Campos A.C.E., Molognoni F., Melo F.H.M., Galdieri L.C., Carneiro C.R.W., D'Almeida V., et al. Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 2007, 9:1111-1121.
17. Kavak S., Ayaz L., Emre M., Inal T., Tamer L., Günay I. The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats. Cell Biochemistry and Function 2008, 26:478-485.
18. Gomez-Mejiba S.E., Zhai Z., Akram H., Deterding L.J., Hensley K., Smith N., et al. Immuno-spin trapping of protein and DNA radicals: "tagging" free radicals to locate and understand the redox process. Free Radic Biol Med 2009, 46:853-865.
19. Trostchansky A., O'Donnell V.B., Goodwin D.C., Landino L.M., Marnett L.J., Radi R., et al. Interactions between nitric oxide and peroxynitrite during prostaglandin endoperoxide H synthase-1 catalysis: a free radical mechanism of inactivation. Free Radic Biol Med 2007, 42:1029-1038.
20. Pacher P., Mukhopadhyay P., Rajesh M., Batkai S., Hasko G., Szabo C. Interplay of superoxide, nitric oxide and peroxynitrite in doxorubicin-induced cell death. FASEB J 2008, 22. 970.912-.
21. Kurien B.T., Scofield R.H. Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Sci 2003, 73:1655-1666.
22. Craig W.Y. Autoantibodies against oxidized low density lipoprotein: a review of clinical findings and assay methodology. J Clin Lab Anal 1995, 9:70-74.
23. Kopkan L., Castillo A., Navar L.G., Majid D.S.A. Enhanced superoxide generation modulates renal function in ANG II-induced hypertensive rats. Am J Physiol Renal Physiol 2006, 290:F80-F86.
24. Brand M.D., Affourtit C., Esteves T.C., Green K., Lambert A.J., Miwa S., et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 2004, 37:755-767.
25. Poyton R.O., Ball K.A., Castello P.R. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab 2009, 20:332-340.
26. Vorbach C., Harrison R., Capecchi M.R. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol 2003, 24:512-517.
27. Bonizzi G., Piette J., Merville M.P., Bours V. Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1. Biochem Pharmacol 2000, 59:7-11.
28. Feng L., Xia Y., Garcia G.E., Hwang D., Wilson C.B. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995, 95:1669-1675.
29. Satoh M., Fujimoto S., Haruna Y., Arakawa S., Horike H., Komai N., et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005, 288:F1144-F1152.
30. Keisari Y., Braun L., Flescher E. The oxidative burst and related phenomena in mouse macrophages elicited by different sterile inflammatory stimuli. Immunobiology 1983, 165:78-89.
31. Rahman I., Yang S.-R., Biswas S.K. Current concepts of redox signaling in the lungs. Antioxid Redox Signal 2006, 8:681-689.
32. Zhu H., Bunn H.F. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 1999, 115:239-247.
33. Wolin M.S., Burke-Wolin T.M., Mohazzab-H K.M. Roles for NAD(P)H oxidases and reactive oxygen species in vascular oxygen sensing mechanisms. Respir Physiol 1999, 115:229-238.
34. Decoursey T.E., Ligeti E. Regulation and termination of NADPH oxidase activity. Cell Mol Life Sci 2005, 62:2173-2193.
35. Zahrt T.C., Deretic V. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid Redox Signal 2002, 4:141-159.
36. Deby C., Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. Biochem Pharmacol 1990, 39:399-405.
37. Steinbeck M.J., Khan A.U., Karnovsky M.J. Extracellular production of singlet oxygen by stimulated macrophages quantified using 9,10-diphenylanthracene and perylene in a polystyrene film. J Biol Chem 1993, 268:15649-15654.
38. Veal E.A., Day A.M., Morgan B.A. Hydrogen peroxide sensing and signaling. Mol Cell 2007, 26:1-14.
39. Valko M., Morris H., Cronin M.T.D. Metals, toxicity and oxidative stress. Curr Med Chem 2005, 12:1161-1208.
40. Pastor N., Weinstein H., Jamison E., Brenowitz M. A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J Mol Biol 2000, 304:55-68.
41. Liochev S.I., Fridovich I. The Haber-Weiss cycle - 70 years later: an alternative view. Redox Rep 2002, 7:55-57.
42. Foreman J., Demidchik V., Bothwell J.H.F., Mylona P., Miedema H., Torres M.A., et al. Reactive oxygen species produced by NADPH oxidase regulate plant cell growth. Nature 2003, 422:442-446.
43. Li J., Stouffs M., Serrander L., Banfi B., Bettiol E., Charnay Y., et al. The NADPH oxidase NOX4 drives cardiac differentiation: Role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell 2006, 17:3978-3988.
44. Geiszt M., Leto T.L. The Nox family of NAD(P)H oxidases: host defense and beyond. J Biol Chem 2004, 279:51715-51718.
45. Salmeen A., Andersen J.N., Myers M.P., Meng T.-C., Hinks J.A., Tonks N.K., et al. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 2003, 423:769-773.
46. Brandon M., Baldi P., Wallace D.C. Mitochondrial mutations in cancer. Oncogene 2006, 25:4647-4662.
47. Stadler K., Bonini M.G., Dallas S., Jiang J., Radi R., Mason R.P., et al. Involvement of inducible nitric oxide synthase in hydroxyl radical-mediated lipid peroxidation in streptozotocin-induced diabetes. Free Radical Biology and Medicine 2008, 45:866-874.
48. Mütze S., Hebling U., Stremmel W., Wang J., Arnhold J., Pantopoulos K., et al. Myeloperoxidase-derived Hypochlorous Acid Antagonizes the Oxidative Stress-mediated Activation of Iron Regulatory Protein 1. Journal of Biological Chemistry 2003, 278:40542-40549.
49. Winterbourn C.C., Vissers M.C., Kettle A.J. Myeloperoxidase. Curr Opin Hematol 2000, 7:53-58.
50. Hampton M.B., Kettle A.J., Winterbourn C.C. Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing. Blood 1998, 92:3007-3017.
51. Lau D., Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006, 111:16-26.
52. Nicholls S.J., Hazen S.L. Myeloperoxidase and Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
53. Eiserich J.P., Baldus S., Brennan M.-L., Ma W., Zhang C., Tousson A., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296:2391-2394.
54. Xu J., Xie Z., Reece R., Pimental D., Zou M.-H. Uncoupling of Endothelial Nitric Oxidase Synthase by Hypochlorous Acid: Role of NAD(P)H Oxidase-Derived Superoxide and Peroxynitrite. Arterioscler Thromb Vasc Biol 2006, 26:2688-2695.
55. Zhang C., Yang J., Jacobs J.D., Jennings L.K. Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. Am J Physiol Heart Circ Physiol 2003, 285:2563-2572.
56. Marsche G., Heller R., Fauler G., Kovacevic A., Nuszkowski A., Graier W., et al. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol 2004, 24:2302-2306.
57. Migliorini P., Pratesi F., Bongiorni F., Moscato S., Scavuzzo M., Bombardieri S. The targets of nephritogenic antibodies in systemic autoimmune disorders. Autoimmun Rev 2002, 1:168-173.
58. Espinosa A., Oke V., Elfving A., Nyberg F., Covacu R., Wahren-Herlenius M. The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. Exp Cell Res 2008, 314:3605-3613.
59. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001, 357:593-615.
60. Kleinert H., Pautz A., Linker K., Schwarz P.M. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol 2004, 500:255-266.
61. Karpuzoglu E., Ahmed S.A. Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: Implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide 2006, 15:177-186.
62. Reilly C.M., Oates J.C., Sudian J., Crosby M.B., Halushka P.V., Gilkeson G.S. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin. Immunol 2001, 98:337-345.
63. Lincoln J., Hoyle C.H.V., Burnstock G. Nitric Oxide in Health and Disease 1997, Cambridge University Press, New York, NY.
64. NOS2 expression profiles. Human Protein Atlas 2005,[cited october 2009];. http://www.proteinatlas.org/tissue_profile.php%3Fantibody_id%3D2014.
65. Xia Y., Zweier J.L. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U.S. A 1997, 94:6954-6958.
66. Gaertner S.A., Janssen U., Ostendorf T., Koch K.M., Floege J., Gwinner W. Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol 2002, 13:2930-2937.
67. Abraham N.G., Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic. Biol. Med 2005, 39:1-25.
68. Wink D.A., Feelisch M., Fukuto J., Chistodoulou D., Jourd'heuil D., et al. The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. Arch Biochem Biophys 1998, 351:66-74.
69. Wink D.A., Mitchell J.B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 1998, 25:434-456.
70. Thomas D.D., Ridnour L.A., Isenberg J.S., Flores-Santana W., Switzer C.H., Donzelli S., et al. The chemical biology of nitric oxide: Implications in cellular signaling. Free Radical Biology and Medicine 2008, 45:18-31.
71. Kharitonov V.G., Sharma V.S., Magde D., Koesling D. Kinetics of nitric oxide dissociation from five- and six-coordinate nitrosyl hemes and heme proteins, including soluble guanylate cyclase. Biochemistry 1997, 36:6814-6818.
72. Padmaja S., Huie R.E. The reaction of nitric oxide with organic peroxyl radicals. Biochem Biophys Res Commun 1993, 195:539-544.
73. Thomas D.D., Ridnour L.A., Espey M.G., Donzelli S., Ambs S., Hussain S.P., et al. Superoxide Fluxes Limit Nitric Oxide-induced Signaling. J. Biol. Chem 2006, 281:25984-25993.
74. Ridnour L.A., Thomas D.D., Mancardi D., Espey M.G., Miranda K.M., Paolocci N., et al. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biological Chemistry 2005, 385:1-10.
75. Salvemini D., Doyle T.M., Cuzzocrea S. Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation. Biochem. Soc. Trans 2006, 34:965-970.
76. Thomas D.D., Ridnour L.A., Isenberg J.S., Flores-Santana W., Switzer C.H., Donzelli S., et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic. Biol. Med 2008, 45:18-31.
77. Leon L., Jeannin J.F., Bettaieb A. Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. Nitric Oxide 2008, 19:77-83.
78. Delgado Alves J., Mason L.J., Ames P.R., Chen P.P., Rauch J., Levine J.S., et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford) 2005, 44:1238-1244.
79. Zou M.H., Yesilkaya A., Ullrich V. Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. Drug Metabolism Reviews 1999, 31:343-349.
80. Goodwin D.C., Landino L.M., Marnett L.J. Reactions of prostaglandin endoperoxide synthase with nitric oxide and peroxynitrite. Drug Metab. Rev 1999, 31:273-294.
81. Weinberg J.B., Granger D.L., Pisetsky D.S., Seldin M.F., Misukonis M.A., Mason S.N., et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L- arginine. J. Exp. Med 1994, 179:651-660.
82. Heery J.M., Kozak M., Stafforini D.M., Jones D.A., Zimmerman G.A., McIntyre T.M., et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. Journal of Clinical Investigation 1995, 96:2322-2330.
83. Keng T., Privalle C.T., Gilkeson G.S., Weinberg J.B. Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. Mol. Med 2000, 6:779-792.
84. Wang H.P., Hsu T.C., Hsu G.J., Li S.L., Tzang B.S. Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice. Eur. J. Pharmacol 2009, 607:102-106.
85. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003, 111:539-552.
86. Reilly C.M., Olgun S., Goodwin D., Gogal R.M., Santo A., et al. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol 2006, 36:1296-1308.
87. Li H.H., Cheng H.H., Sun K.H., Wei C.C., Li C.F., Chen W.C., et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin. Immunol 2008, 129:277-285.
88. Takeda Y., Takeno M., Iwasaki M., Kobayashi H., Kirino Y., Ueda A., et al. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clin Exp Immunol 2004, 138:237-244.
89. Lui S.L., Tsang R., Wong D., Chan K.W., Chan T.M., Fung P.C., et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002, 11:411-418.
90. Yu C.C., Yang C.W., Wu M.S., Ko Y.C., Huang C.T., Hong J.J., Huang C.C. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med 2001, 138:69-77.
91. Reilly C.M., Farrelly L.W., Viti D., Redmond S.T., Hutchison F., Ruiz P., et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 2002, 61:839-846.
92. Oates J.C., Ruiz P., Alexander A., Pippen A.M., Gilkeson G.S. Effect of late modulation of nitric oxide production on murine lupus. Clin. Immunol. Immunopathol 1997, 83:86-92.
93. Gilkeson G.S., Mudgett J.S., Seldin M.F., Ruiz P., Alexander A.A., Misukonis M.A., et al. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med 1997, 186:365-373.
94. Njoku C., Self S.E., Ruiz P., Hofbauer A.F., Gilkeson G.S., Oates J.C. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med 2008, 56:911-919.
95. Njoku C.J., Patrick K.S., Ruiz P., Oates J.C. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J. Investig. Med 2005, 53:347-352.
96. Zou M.H., Cohen R., Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004, 11:89-97.
97. Zou M.H., Shi C., Cohen R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest 2002, 109:817-826.
98. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med 1994, 179:1317-1330.
99. Boyd C.S., Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol. Chem 2002, 383:411-423.
100. Oates J.C., Gilkeson G.S. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J. Investig. Med 2004, 52:62-71.
101. Singh A.K. Lupus in the Fas lane? J.R. Coll. Physicians Lond 1995, 29:475-478.
102. Ohmori H., Oka M., Nishikawa Y., Shigemitsu H., Takeuchi M., Magari M., et al. Immunogenicity of autologous IgG bearing the inflammation-associated marker 3-nitrotyrosine. Immunol. Lett 2005, 96:47-54.
103. Oates J.C., Gilkeson G.S. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol 2006, 121:243-250.
104. Oates J.C., Christensen E.F., Reilly C.M., Self S.E., Gilkeson G.S. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. Proceedings of the Association of American Physicians 1999, 111:611-621.
105. Oates J.C., Levesque M.C., Hobbs M.R., Smith E.G., Molano I.D., Page G.P., et al. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J Rheumatol 2003, 30:60-67.
106. Kuhn A., Fehsel K., Lehmann P., Krutmann J., Ruzicka T., Kolbbachofen V. Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus. Journal of Investigative Dermatology 1998, 111:149-153.
107. Oates J.C., Shaftman S.R., Self S.E., Gilkeson G.S. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum 2008, 58:263-272.
108. Furusu A., Miyazaki M., Abe K., Tsukasaki S., Shioshita K., Sasaki O., et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney International 1998, 53:1760-1768.
109. Wang J.S., Tseng H.H., Shih D.F., Jou H.S., Ger L.P. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 1997, 77:404-411.
110. Bollain Y.G.J.J., Ramirez-Sandoval R., Daza L., Esparza E., Barbosa O., Ramirez D., et al. Widespread expression of inducible NOS and citrulline in lupus nephritis tissues. Inflammation Research 2009, 58:61-66.
111. Zheng L., Sinniah R. Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 2006, 37:637-647. S, I. H. H.
112. Batuca J.R., Ames P.R., Amaral M., Favas C., Isenberg D.A., Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48:26-31.
113. Moore K.P., Darley-Usmar V., Morrow J., Roberts L.J. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circulation Research 1995, 77:335-341.
114. Huber J., Bochkov V.N., Binder B.R., Leitinger N. The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. Antioxid Redox Signal 2003, 5:163-169.
115. Fukunaga M., Makita N., Roberts L.J.d., Morrow J.D., Takahashi K., Badr K.F. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. American Journal of Physiology 1993, 264:C1619-C1624.
116. Lopez L.R., Kobayashi K., Matsunami Y., Matsuura E. Immunogenic Oxidized Low-density Lipoprotein/beta2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis. Clin. Rev. Allergy Immunol 2009, 37:12-19.
117. Peng D.Q., Brubaker G., Wu Z., Zheng L., Willard B., Kinter M., et al. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler. Thromb. Vasc. Biol 2008, 28:2063-2070.
118. Nicholls S.J., Hazen S.L. Myeloperoxidase, modified lipoproteins, and atherogenesis. J. Lipid Res 2009, 50 Suppl:S346-S351.
119. El-Magadmi M., Bodill H., Ahmad Y., Durrington P.N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110:399-404.
120. Clancy R., Marder G., Martin V., Belmont H.M., Abramson S.B., Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 2001, 44:1203-1208.
121. Belmont H.M., Levartovsky D., Goel A., Amin A., Giorno R., Rediske J., et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1810-1816.
122. Khan F., Ali R. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J Biochem Mol Biol 2006, 39:189-196.
123. Dixit K., Ali R. Role of nitric oxide modified DNA in the etiopathogenesis of systemic lupus erythematosus. Lupus 2004, 13:95-100.
124. Habib S., Moinuddin, Ali R. Peroxynitrite-modified DNA: a better antigen for systemic lupus erythematosus anti-DNA autoantibodies. Biotechnol Appl Biochem 2006, 43:65-70.
125. Nagy G., Koncz A., Perl A. T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol 2003, 171:5188-5197.
126. Gergely P., Niland B., Gonchoroff N., Pullmann R., Phillips P.E., Perl A. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol 2002, 169:1092-1101.
127. Nagy G., Barcza M., Gonchoroff N., Phillips P.E., Perl A. Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol 2004, 173:3676-3683.
128. Gergely P., Grossman C., Niland B., Puskas F., Neupane H., Allam F., et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:175-190.
129. Fernandez D.R., Telarico T., Bonilla E., Li Q., Banerjee S., Middleton A., et al. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009, 182:2063-2073.